Ocuphire Pharma Investor Presentation Deck

Landscape of Non-Invasive Therapies for Diabetic Retinopathy Ocuphire's APX3330 is the Most Advanced and The Only Dual Mechanism Oral Drug Candidate Company Ocuphire Roche PHARMA BAYER BAYER Valo Ocuphire OCUTERRA THERAPEUTICS Drug APX3330 RG7774 Target/MOA Ref-1 inhibitor (Anti-VEGF and Anti-inflammatory) CB2 receptor (cannabinoid) BAY1101042 Guanylate Cyclase activator OPL-0401 ROCK 1/2 inhibitor OTT 166 Integrin inhibitor Indication DR DR DR DR DR Route of Administration Oral Oral Company websites and www.clinical trials.gov (as of July 31, 2023) Oral Oral Eyedrop Phase 1 Phase 2 Phase 3 ✓ 2022 ✓ ✓ ✓ ✓ ✓ Primary Endpoint/ Secondary Endpoints 2020: 2-step DRSS @wk24 2020: 2-step DRSS @wk36 2021: 2-step DRSS @wk24 2021: 2-step DRSS @wk24 Note: Two Tyrosine Kinase and a Plasma Kallikrein Inhibitors failed as orals in Phase 2 due to dose limiting adverse events (e.g., liver and cardiovascular) Completed Ongoing 2022: 2-step DRSS @wk24 APX3330 Differentiation ➤ Mechanism: Dual MOA targeting validated retinal pathways of angiogenesis and inflammation Human exposure: >10,000 subject days of systemic exposure in humans at 600mg/day dose Favorable safety and tolerability X Discontinued 12

View entire presentation